Kazia Therapeutics Limited

0.41 USD
+0.03 (+8.68%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kazia Therapeutics Limited stock is up 79.57% since 30 days ago. The next earnings date is Sep 3, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.46% of the previous 25 July’s closed higher than June. 100% of analysts rate it a buy.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway. It is also developing EVT801, an investigational new drug for various forms of cancer.